Nuvalent (NUVL) Expected to Announce Quarterly Earnings on Thursday

Nuvalent (NASDAQ:NUVL) is expected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Nuvalent to post earnings of ($1.48) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 9:30 AM ET.

Nuvalent Stock Performance

Shares of NUVL opened at $102.36 on Thursday. The firm has a market cap of $7.44 billion, a P/E ratio of -19.24 and a beta of 1.32. Nuvalent has a 52 week low of $55.53 and a 52 week high of $113.01. The firm’s 50-day simple moving average is $103.53 and its 200 day simple moving average is $93.85.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. HC Wainwright lifted their price target on Nuvalent from $130.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, November 17th. The Goldman Sachs Group boosted their target price on shares of Nuvalent from $120.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. UBS Group reaffirmed a “buy” rating on shares of Nuvalent in a research report on Wednesday, December 17th. JPMorgan Chase & Co. cut their price objective on shares of Nuvalent from $147.00 to $145.00 and set an “overweight” rating for the company in a report on Friday, December 19th. Finally, Truist Financial set a $140.00 price target on shares of Nuvalent in a research report on Monday, November 24th. Fifteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Nuvalent presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.33.

Insider Transactions at Nuvalent

In other Nuvalent news, Director Matthew Shair sold 5,850 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $109.37, for a total transaction of $639,814.50. Following the completion of the transaction, the director owned 1,377,194 shares of the company’s stock, valued at approximately $150,623,707.78. The trade was a 0.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James E. Flynn sold 742,574 shares of Nuvalent stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $95.44, for a total transaction of $70,871,262.56. Following the sale, the director directly owned 8,299,225 shares in the company, valued at $792,078,034. This trade represents a 8.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 826,537 shares of company stock valued at $79,414,026. Company insiders own 10.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in NUVL. Wellington Management Group LLP grew its stake in shares of Nuvalent by 7.0% in the fourth quarter. Wellington Management Group LLP now owns 2,461,823 shares of the company’s stock worth $247,635,000 after purchasing an additional 160,958 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Nuvalent by 32.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock worth $221,826,000 after purchasing an additional 545,542 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Nuvalent by 18.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,146,938 shares of the company’s stock worth $215,962,000 after buying an additional 336,518 shares during the period. RA Capital Management L.P. raised its stake in Nuvalent by 50.8% during the fourth quarter. RA Capital Management L.P. now owns 1,880,057 shares of the company’s stock worth $189,115,000 after buying an additional 633,601 shares during the last quarter. Finally, State Street Corp lifted its holdings in Nuvalent by 18.4% in the fourth quarter. State Street Corp now owns 1,864,675 shares of the company’s stock valued at $187,568,000 after buying an additional 289,928 shares during the period. Institutional investors own 97.26% of the company’s stock.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.